 |
Find a Stock's Home Page |
|
| News |
San Diego, CA 7/07/2009
Generex BioTech Corp. shares are rallying again today, most likely fueled by the June announcement that the company is developing a new vaccine technology not based on biology, but rather, chemistry. As an alternative form of vaccine production, Antigen Express (a wholly owned subsidiary of Generex Biotechnology) can utilize lab equipment to join amino acids into peptides that stimulate an immune response to specific threats, including the flu. If Antigen Express and Generex could develop an H1N1 'swine flu' vaccine with this technology, wide production of such a vaccine could take place soon.
Antigen Express has already assisted in the development of Phase I trial of Generex Biotech's prostate cancer vaccine, which showed positive results. The immunotherapeutic peptide AE37 is also being developed by the company for use as a treatment of other forms of cancer.
Investors and traders are invited to learn more about Generex Biotechnology by subscribing to the free Small Cap Network Newsletter, which offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: access.smallcapnetwork.com/s/
About Generex Biotechnology Corporation
Generex (GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
Generex's flagship product is an oral insulin names Generex Oral-lyn. It's currently available for in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes. It's also in Phase III clinical trials in several countries around the world.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Penny-Stock-GNBT-Climbs-in-a-Sellers-Market-and-NEPH-Holds-Its-Own/s/article/view/p/mid/2/id/42/
